Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Cash from Financing Activities (2017 - 2025)

Historic Cash from Financing Activities for Aclaris Therapeutics (ACRS) over the last 9 years, with Q3 2025 value amounting to -$3.0 million.

  • Aclaris Therapeutics' Cash from Financing Activities fell 1393636.36% to -$3.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $71.3 million, marking a year-over-year increase of 142494000.0%. This contributed to the annual value of $74.5 million for FY2024, which is 17909.83% up from last year.
  • As of Q3 2025, Aclaris Therapeutics' Cash from Financing Activities stood at -$3.0 million, which was down 1393636.36% from -$9000.0 recorded in Q2 2025.
  • Aclaris Therapeutics' 5-year Cash from Financing Activities high stood at $135.9 million for Q2 2021, and its period low was -$11.6 million during Q3 2021.
  • Moreover, its 5-year median value for Cash from Financing Activities was -$2000.0 (2021), whereas its average is $21.7 million.
  • Its Cash from Financing Activities has fluctuated over the past 5 years, first surged by 15210408.16% in 2024, then crashed by 1393636.36% in 2025.
  • Aclaris Therapeutics' Cash from Financing Activities (Quarter) stood at -$2000.0 in 2021, then skyrocketed by 1950.0% to $37000.0 in 2022, then surged by 32.43% to $49000.0 in 2023, then soared by 152104.08% to $74.6 million in 2024, then plummeted by 104.08% to -$3.0 million in 2025.
  • Its Cash from Financing Activities stands at -$3.0 million for Q3 2025, versus -$9000.0 for Q2 2025 and -$275000.0 for Q1 2025.